Atlas One · Host Biology · Scale 03 — Molecular

JAK2

JAK2 non-receptor tyrosine kinase mediates EPO, TPO, and cytokine receptor signaling via STAT5/STAT3; JAK2 V617F pseudokinase domain mutation causes constitutive kinase activity in polycythemia vera (>95%), essential thrombocythemia, and myelofibrosis; ruxolitinib is approved.

Also known as: JAK2, Janus kinase 2, JAK2 V617F, ruxolitinib, JAK-STAT signaling, polycythemia vera JAK2, myeloproliferative neoplasm JAK2

Scale 03 — MolecularScale
draftStatus
2026-06-06Last Reviewed
This is an auto-generated stub page built from atlas entry frontmatter. A richer hand-crafted page is planned. See the atlas source for the full entry including detailed body sections.
jak2

JAK2

JAK2 non-receptor tyrosine kinase mediates EPO, TPO, and cytokine receptor signaling via STAT5/STAT3; JAK2 V617F pseudokinase domain mutation causes constitutive kinase activity in polycythemia vera (>95%), essential thrombocythemia, and myelofibrosis; ruxolitinib is approved.

Entry Metadata

FieldValue
IDjak2
NameJAK2
Statusdraft
Last reviewed2026-06-06
Atlas01-human
Scale03-molecular

Cross-Atlas Connections

connects-toStat3 connects-toErythropoietin connects-toIl 6 connects-toMtor

Sources